Additionally, Webster et al. [22] reported that the addition of PD1 and CTLA-4 blockade to Blinatumomab was significantly associated with improved CR rate, MRD negativity and OS in R/R adult ALL. The gene discussed is PDCD1; the disease is acute lymphoblastic leukemia.